Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Rimm

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
British Journal of Cancer|July 18, 2014
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling errorM Shipitsin, C Small, S Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2023
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinomaN Gavrielatou, E Fortis, A Spathis, et al.
Nature Communications|August 12, 2018
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockersS N Gettinger, J Choi, N Mani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancerA C Garrido-Castro, S E Kim, T Li, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
British Journal of Cancer|July 18, 2014
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling errorM Shipitsin, C Small, S Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2023
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinomaN Gavrielatou, E Fortis, A Spathis, et al.
Nature Communications|August 12, 2018
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockersS N Gettinger, J Choi, N Mani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancerA C Garrido-Castro, S E Kim, T Li, et al.
Pageof 8